Bartlett & Co Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bartlett & Co Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$245K	Sell	570 -31	-5%	-$14.5K	﹤0.01%	427
2025 Q4	$272K	Buy	601 +1	+0.2%	+$431	﹤0.01%	415
2025 Q3	$235K	Buy	600 +13	+2%	+$5.43K	﹤0.01%	428
2025 Q2	$261K	Hold	587	–	–	﹤0.01%	409
2025 Q1	$285K	Buy	587 +230	+64%	+$107K	﹤0.01%	403
2024 Q4	$144K	Hold	357	–	–	﹤0.01%	490
2024 Q3	$166K	Buy	357 +6	+2%	+$2.88K	﹤0.01%	473
2024 Q2	$165K	Buy	351 +96	+38%	+$41.7K	﹤0.01%	460
2024 Q1	$107K	Buy	255 +55	+28%	+$23.3K	﹤0.01%	542
2023 Q4	$81.9K	Hold	200	–	–	﹤0.01%	606
2023 Q3	$69.5K	Hold	200	–	–	﹤0.01%	595
2023 Q2	$70.4K	Hold	200	–	–	﹤0.01%	600
2023 Q1	$63K	Hold	200	–	–	﹤0.01%	535
2022 Q4	$57.8K	Hold	200	–	–	﹤0.01%	560
2022 Q3	$57.9K	Hold	200	–	–	﹤0.01%	546
2022 Q2	$56.4K	Hold	200	–	–	﹤0.01%	551
2022 Q1	$52.2K	Buy	+200	New	+$47.5K	﹤0.01%	578
2021 Q3	–	Sell	-4	Closed	-$807	–	1082
2021 Q2	$807	Sell	4 -50	-93%	-$10.5K	﹤0.01%	978
2021 Q1	$11.6K	Hold	54	–	–	﹤0.01%	712
2020 Q4	$12.8K	Buy	54 +4	+8%	+$918	﹤0.01%	708
2020 Q3	$13.6K	Hold	50	–	–	﹤0.01%	658
2020 Q2	$14.5K	Buy	+50	New	+$13.6K	﹤0.01%	646
2019 Q3	–	Sell	-34	Closed	-$6.24K	–	938
2019 Q2	$6.24K	Buy	+34	New	+$5.94K	﹤0.01%	617

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bartlett & Co Wealth Management's VRTX Position: Q1 2026 in Review

Bartlett & Co Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 5.2% in Q1 2026, selling an estimated $14.5K and leaving 570 shares worth $245K. The position accounts for ﹤0.01% of the portfolio, ranked #427.

Bartlett & Co Wealth Management first reported a position in VRTX in Q2 2019 and has held it in 23 quarters since. The position peaked at $285K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Bartlett & Co Wealth Management held 570 shares of Vertex Pharmaceuticals worth $245K as of Q1 2026.
Bartlett & Co Wealth Management sold 31 Vertex Pharmaceuticals shares in Q1 2026, an estimated $14.5K.
Vertex Pharmaceuticals made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q1 2026, its #427 holding.
Bartlett & Co Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 23 quarters since.
Bartlett & Co Wealth Management's Vertex Pharmaceuticals position peaked at $285K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.